Abstract 217P
Background
With conditional reprogramming (CR) technique to generate continuous primary cancer cell cultures from bladder cancer patients’ urine samples, we aimed to establish a novel in vitro model by a rapid and non-invasive method to predict clinical response to anti-tumor drugs including immunotherapy and provide drug guidance for patients.
Methods
Patients included were all diagnosed with bladder cancer, among which were 54 high grade and 14 low grade. Urine and tumor samples were collected before therapeutic treatment. The overall success rate was summarized. Whole-exome sequencing (WES) and short tandem repeat (STR) analysis were utilized to confirm the authentication of CR cultures (CRCs). Dose-response measurements were used to generate drug sensitivity scores. Expression of PD-L1 on the cell surface of urine CRCs after IFN-γ treatment is evaluated with flow cytometry.
Results
The overall success rate of establishing urine CRCs was 87.2% (68/78), with 93.1% (54/58) of high grade bladder cancer, 70.0% (14/20) of low grade bladder cancer. Importantly, the in vitro drug sensitivity results of the urine-derived cells exhibited strong consistency (78%) with the clinical responses to treatment, indicating their potential for guiding patient-specific therapeutic strategies. Furthermore, we revealed that IFN-γ-stimulated PD-L1 expression on urine CRCs could predict the prognosis of bladder cancer patients and exhibited predictive value for ICI response in bladder cancer patients with a significant consistency of 88%, highlighting their clinical relevance.
Conclusions
Our study demonstrates the successful establishment of a reliable and patient-specific bladder cancer cell model derived from urine samples which serve to guide anti-tumor drugs and immunotherapeutic interventions. The findings underscore the clinical utility and translational potential of urine-derived cells for personalized bladder cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract